Bcl-2 Family Protein Inhibitor
Showing 1 - 25 of >10,000
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +1 more
Nov 8, 2022
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Novel Antidiabetic Drug Combined With Angiotensin
Recruiting
- Type 2 Diabetes
- Antidiabetic Drugs
-
Beijing, Beijing, China
- +1 more
Jun 20, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial (LP-108, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- (no location specified)
Nov 29, 2022
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Navitoclax
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- (no location specified)
Jul 18, 2023
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma Trial run by the National Cancer Institute
Recruiting
- Astrocytoma, Grades II, III and IV
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Bcl-2 Inhibitor GDC-0199
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 29, 2021
Mantle Cell Lymphoma Trial in United States (Venetoclax, Bendamustine, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Venetoclax
- +2 more
-
Urbana, Illinois
- +9 more
Nov 10, 2022
T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)
Recruiting
- T-lymphoblastic Lymphoma
- +5 more
- BCL2 Inhibitor plus IM2 regimen
-
Shanghai, Shanghai, ChinaShanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023
Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 23, 2023
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen
Not yet recruiting
- Metastatic Endometrial Carcinoma
- +7 more
- Biopsy
- +5 more
- (no location specified)
Jan 18, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- collection of biological samples and clinical data
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 5, 2021
Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Decitabine for Injection
- VENCLYXTO
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023
Multiple Myeloma Trial in Rochester (procedure, biological, drug)
Not yet recruiting
- Multiple Myeloma
- Biospecimen Collection
- +12 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Sep 15, 2023
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,
Not yet recruiting
- Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
- (no location specified)
Jan 22, 2023
Advanced Breast Cancer Trial in Changsha (TQB3909 tablets)
Recruiting
- Advanced Breast Cancer
- TQB3909 tablets
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 16, 2023